A HealthTech that found its flow: Realigning strategy, evidence, and growth

When we first met this UK-based healthtech company, they had everything you’d expect from a high-potential innovator:

• A clinically validated digital therapeutic platform for long-term condition management

• 35 employees across product, data science, and commercial functions

• Backed by ~£3M investor funding

• Their product was delivering real-world outcomes, reducing hospital admissions by 18% in early pilots.

Yet despite this promise, progress felt stuck. Investor conversations were slow to advance, commercial uptake was uneven, and the sense of direction across the organisation had started to blur.

__________________________

They weren’t sinking, but they were swimming hard against the current.

__________________________

The challenge

The company’s challenges weren’t unusual for fast-growing companies in the health ecosystem. They sat at the intersection of science-system-story, but each was pulling in a slightly different direction.

Through our strategic diagnostic, we identified three currents that were shaping (and slowing) their growth:

1. Market fit drift: Their messaging was still anchored in clinical validation and proof rather than buyer priorities and value. The science was robust, but the commercial story wasn’t resonating.

2. Fragmented messaging: Across marketing, partnerships, and investor decks, the narrative shifted. The commercial team emphasised efficiency savings, while the product team spoke about engagement metrics. Each was accurate, but inconsistent.

3. Growth overstretch: With limited resources, they were pursuing three market segments (NHS Trusts, insurers, and employers). Energy and efforts across the teams were spread wide, not deep.

_______________________

These are common symptoms of scale turbulence, when momentum creates movement in multiple directions at once.

__________________________

The intervention

We started by slowing things down to gain clarity. Through structured workshops and stakeholder interviews, we built a growth compass: a visual framework aligning market focus, evidence, and story.

Together, we defined three strategic anchors:

• Focus: Concentrate growth efforts on one segment, where evidence and relationships were already strongest.

• Evidence: Translate clinical outcomes (–18% hospital admissions, +25% adherence) into buyer-centric metrics like cost savings per patient and workforce impact. Metrics buyers care about.

• Message: Align every external narrative around that shared definition of impact, connecting clinical proof to operational benefits and ROI.

___________________________

We didn’t rewrite their strategy, it was about rediscovering coherence.

___________________________

The outcome

Within 90 days, signs of renewed buoyancy appeared:

• Investor follow-ups increased by 30% as the growth story became clearer.

• Pilot-to-contract conversion improved from 1 in 6 to 1 in 3.

• The leadership team reported “a shared language for growth”.

By month four, their growth was steady and focused. They hadn’t changed their product but how they navigated the system.

___________________________

This is what strategic buoyancy looks like in practice: progress powered by clarity, not just effort.

___________________________

Closing reflection

When teams pause to map their currents of market, evidence, message, they’ll rediscover the natural flow between innovation and impact.

The key isn’t to swim harder. It’s to pause, understand the water, and choose your direction with intent.

At Buoyancy, we help teams do exactly that, to stay afloat, find their flow, and move forward with clarity and confidence.

If your growth feels harder than it should, let’s explore what might be holding your buoyancy back.